Paul R. Fonteyne - Jan 1, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Paul Fonteyne
Stock symbol
APLS
Transactions as of
Jan 1, 2022
Transactions value $
$0
Form type
4
Date filed
1/4/2022, 08:28 PM
Previous filing
Aug 11, 2021
Next filing
Jan 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +4.23K +84.6% $0.00 9.23K Jan 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $0 +8.55K $0.00 8.55K Jan 1, 2022 Common Stock 8.55K $47.28 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents a restricted stock unit grant made on 1/1/2022 that fully vest on the first anniversary of the date of grant, subject to continued service as a director.
F2 This represents a non-qualified stock option grant made on 1/1/2022 that vests quarterly over 1 year from the date of grant, subject to continued service as a director, and expires seven years from the date of grant.